This Blog Is Powered By Life Technology™. Visit Life Technology™ At www.lifetechnology.com Subscribe To This Blog Via Feedburner / Atom 1.0 / RSS 2.0.
Sunday, September 8, 2019
New KEYNOTE 021 data shows no association with tumor mutational burden
Researchers had previously reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based chemotherapy in untreated advanced nonsquamous non-small cell lung cancer patients. Today at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, the same research group presented new data from two new groups of patients from this trial.